Bio-Imaging Technologies, Inc announces that, in response to another unsolicited offer received by etrials Worldwide, Inc from an unrelated third party, etrials has informed Bio-Imaging that its board of directors has deemed the unsolicited offer a superior proposal, as defined in the merger agreement between the parties, and has entered into a merger agreement with such unrelated third party. In connection with the termination of the Bio- Imaging merger agreement, etrials is obligated to pay to Bio-Imaging a termination fee of $500,000 and reimburse Bio-Imaging for reasonable out of pocket expenses up to $250,000 on or before June 2, 2009.

Mark L Weinstein, president and chief executive officer of BioClinica said, "We have decided it would not be in the best interest of our shareholders to pursue this acquisition further. Although we are disappointed with the outcome, we will continue to actively look for other acquisitions that would add value and expand our eClinical services offering."

Bio-Imaging Techno is a leading global provider of clinical trials services, helping to support drug and product development efforts through all phases of the clinical trial process.